Matinas BioPharma Holdings, a clinical-stage biopharmaceutical company specializing in revolutionary therapies utilizing its lipid nanocrystal (LNC) platform technology, has disclosed encouraging outcomes from an in vivo animal study involving an oral LNC formulation of docetaxel, a widely recognized chemotherapeutic agent employed in the treatment of various metastatic and unresectable tumors. Subsequent to this announcement, Matinas BioPharma Holdings’ stock experienced a significant surge earlier today.
At the time of this publication, Matinas BioPharma Holdings Inc stock (MTNB) has witnessed a surge.
Matinas BioPharma Holdings Inc
Current Price: $0.28
Change : +0.03
Change (%): (12.92%)
Volume: 9.2M
Source: Tomorrow Events Market Data
At present, docetaxel is administered intravenously and may be accompanied by substantial side effects and toxicities.
Study Design
Objective: To document the effectiveness of an oral LNC docetaxel formulation in targeting and treating tumors, incorporating both negative (untreated) and positive (IV docetaxel) controls.
Syngeneic tumor model (C57BL/6 mice injected with B16F10 murine melanoma cells)
Four treatment groups:
1. Untreated controls
2. Low-dose oral LNC docetaxel
3. High-dose oral LNC docetaxel
4. IV docetaxel
Initiation of oral LNC and IV docetaxel dosing on Day 5 following tumor cell injection
Daily dosing of low-dose and high-dose oral LNC arms extended through Day 14
Administration of IV docetaxel on Day 5 and Day 10
Regular measurement of tumor volume (caliper measurements) throughout the treatment course
Continuous monitoring of toxicity during treatment, along with evaluation of hematologic parameters on Day 14
Animal sacrifice scheduled for Day 14
Measurement of tumor volume on Day 14
Key Findings
Effectiveness: The anti-tumor effect of daily oral LNC docetaxel in both the high-dose and low-dose arms demonstrated comparable results to IV docetaxel. Statistically significant reductions in tumor volume were observed at Day 14 compared to untreated controls (high dose oral LNC -63%; low dose oral LNC -57%; IV docetaxel -68%), along with similar reductions in tumor weight at Day 14.
Safety: No indications of systemic toxicities were recorded. Body weight remained stable throughout the treatment period, and hematologic parameters mirrored those of untreated controls.
Potential Future Steps
Potential future endeavors for Matinas encompass the evaluation of the current LNC docetaxel formulation in other tumor models, as well as the assessment of extended treatment regimens to validate the absence of toxicity. Additionally, Matinas intends to explore the potential anti-tumor activity of LNC formulations involving small oligonucleotides.
Dr. James J. Ferguson, Chief Medical Officer of Matinas, remarked, “We believe this is a significant stride forward for Matinas’ distinctive drug delivery platform, expanding beyond our achievements in infectious disease. It provides compelling proof-of-principle that orally administered LNCs can effectively target tumors and deliver small molecule therapeutics to those tumors.”
